Study S000420

A 12-Week Extension Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT05292911
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 64
Start: 2022-03-09
Primary completion: 2022-10-31
Lead sponsor: Altimmune, Inc.
Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: DRUG:ALT-801; OTHER:Placebo
Results posted: FALSE

Registered primary outcomes

The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) [Up to Day 110]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010027	Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. Browne SK, JHEP reports : innovation in hepatology	2025	Randomized trial	PMID 41113119 DOI	cites ClinicalTrials.gov:NCT05292911; registry reference DERIVED:41113119